Shareholders are entitled to have a matter addressed by the Annual General Meeting as long as their request has been received by the Board of Directors by 10 March 2016. The Board of Directors can be contacted by email at: styrelsen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Greg Batcheller, Medicon Village, 223 81 Lund, Sweden.
The AGM on 30 Mars 2015 resolved that NeuroVive shall have a Nomination Committee comprising one member of each of the three largest shareholders in terms of voting rights based on ownership statistics maintained by Euroclear Sweden AB as of 30 June 2015. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee shall transfer to that member who is the next largest shareholder in terms of voting rights. The Nomination Committee’s period of office runs until a new Nomination Committee has been appointed.
The Nomination Committee for the 2016 AGM comprises:
- Michael Vickers (Chairman) appointed by Maas Biolab LLC / Marcus Keep,
- Anders Ermén appointed by Baulos Capital Belgium SA,
- Tomas Hagström appointed by Eskil Elmér.
In total, the Nomination Committee represents some 28 % of the votes in NeuroVive as of 30 June 2015.
The Nomination Committee’s task ahead of the AGM 2016 is to prepare proposals on the following matters to present to the AGM for resolution:
- Propose the Chairman of the AGM,
- Propose the number of Board members and, where applicable, the number of Auditors,
- Propose remuneration to Board members and remuneration to Committee members,
- Propose remuneration to the Auditors,
- Propose the Chairman of the Board and other Board members and, where applicable, Auditors,
- Propose guidelines for appointing members of the Nomination Committee and the assignments of the Nomination Committee,
- Propose remuneration to the members of the Nomination Committee.
Shareholders wishing to make proposals on the above matters can contact the Committee by email at: valberedningen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81 Lund, Sweden. In order for the Nomination Committee to consider the proposals received with due care, proposals should be received by the Nomination Committee by no later than 1 February 2016.
About NeuroVive Pharmaceutical
NeuroVive Pharmaceutical AB (publ) is a mitochondrial medicine company committed to the discovery and development of therapeutic applications for mitochondrial medicine in areas of significant unmet clinical need. NeuroVive’s business strategy focuses on maximising value from its projects through strategic partnerships and outlicensing.
NeuroVive’s portfolio, containing three cyclophilin D candidates in clinical and preclinical development, is fuelled by three additional drug discovery platforms in neurology, mitochondrial disorders and organ protection. NeuroVive’s product CicloMulsion® is being evaluated in an ongoing Phase II study, CiPRICS, in acute kidney injury during major surgery. The NeuroSTAT® product is currently being evaluated in a Phase II study in traumatic brain injury. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
For Investor Relations and media questions, please contact:
Johannes Nebel, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s Chairman Gregory Batcheller at the above contact.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 16 Oct 2015, at 08.30 a.m. CET.